This topic contains a solution. Click here to go to the answer

Author Question: A patient with Parkinson's disease is taking levodopa/carbidopa (Sinemet) and reports occasional ... (Read 139 times)

stock

  • Hero Member
  • *****
  • Posts: 573
A patient with Parkinson's disease is taking levodopa/carbidopa (Sinemet) and reports occasional periods of loss of drug effect lasting from minutes to several hours.
 
  The nurse questions the patient further and discovers that these episodes occur at different times related to the medication administration. The nurse will contact the provider to discuss:
  a. administering a catechol-O-methyltransferase (COMT) inhibitor, such as entacapone.
  b. adding the DA-releasing agent amantadine to the regimen.
  c. giving a direct-acting dopamine agonist.
  d. shortening the dosing interval of levodopa/carbidopa.

Question 2

A group of nursing students asks a nurse to explain the blood-brain barrier. The nurse would be correct to say that the blood-brain barrier:
 
  a. prevents some potentially toxic substances from crossing into the central nervous system.
  b. causes infants to be less sensitive to CNS drugs and thus require larger doses.
  c. allows only ionized or protein-bound drugs to cross into the central nervous system.
  d. prevents lipid-soluble drugs from entering the central nervous system.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

raenoj

  • Sr. Member
  • ****
  • Posts: 340
Answer to Question 1

ANS: A
This patient is describing abrupt loss of effect, or the off phenomenon, which is treated with entacapone or another COMT inhibitor. Amantadine is used to treat dyskinesias. A direct-acting dopamine agonist is useful for gradual loss of effect, which occurs at the end of the dosing interval as the dose is wearing off. Shortening the dosing interval does not help with abrupt loss of effect.

Answer to Question 2

ANS: A
The blood-brain barrier can prevent some drugs and some toxic substances from entering the CNS. The blood-brain barrier in infants is not fully developed, so infants are more sensitive to CNS drugs and often require lower doses. The blood-brain barrier prevents highly ionized and protein-bound drugs from crossing into the CNS and allows lipid-soluble drugs and those that can cross via specific transport systems to enter.




stock

  • Member
  • Posts: 573
Reply 2 on: Jul 23, 2018
Gracias!


bdobbins

  • Member
  • Posts: 326
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

When intravenous medications are involved in adverse drug events, their harmful effects may occur more rapidly, and be more severe than errors with oral medications. This is due to the direct administration into the bloodstream.

Did you know?

In most cases, kidneys can recover from almost complete loss of function, such as in acute kidney (renal) failure.

Did you know?

Multiple experimental evidences have confirmed that at the molecular level, cancer is caused by lesions in cellular DNA.

Did you know?

Illness; diuretics; laxative abuse; hot weather; exercise; sweating; caffeine; alcoholic beverages; starvation diets; inadequate carbohydrate consumption; and diets high in protein, salt, or fiber can cause people to become dehydrated.

Did you know?

Congestive heart failure is a serious disorder that carries a reduced life expectancy. Heart failure is usually a chronic illness, and it may worsen with infection or other physical stressors.

For a complete list of videos, visit our video library